4 March 2013Big Pharma

India rejects Bayer plea over compulsory licence

India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

More on this story

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

More on this story

Bayer’s compulsory licence appeal set to start in India

29 October 2013 A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.

Bayer takes another swipe at Nexavar compulsory licence

15 October 2013 Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?